Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Xeris Biopharma Holdings, Inc. (XERS) trades at $8.60 with AI Score 35/100 (Grade D). Xeris Biopharma Holdings, Inc. is a biopharmaceutical company specializing in therapies for endocrinology, neurology, and gastroenterology. Market cap: $1.48B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for XERS: XERS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates XERS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
XERS: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Xeris Biopharma Holdings, Inc. (XERS) Healthcare & Pipeline Overview
Xeris Biopharma Holdings, Inc. stands out in the biopharmaceutical industry with its innovative therapies for severe hypoglycemia and other conditions, supported by proprietary formulation technologies that enhance patient care and treatment efficacy.
What Is the Investment Thesis for XERS?
Xeris Biopharma Holdings, Inc. presents a compelling investment thesis driven by its innovative product portfolio and growth potential in the biopharmaceutical sector. The company has a market capitalization of $1.48B and a gross margin of 81.6%, indicating strong profitability potential. Key growth catalysts include the increasing adoption of Gvoke in the diabetes management market, which is expected to expand significantly as awareness of severe hypoglycemia rises. Additionally, the ongoing development of new indications for Recorlev and the potential for new product launches using XeriSol and XeriJect technologies could enhance revenue streams. However, investors should be mindful of the competitive landscape and regulatory hurdles that may impact product approvals and market penetration. Overall, Xeris's focus on innovative therapies positions it well for future growth, but careful consideration of market dynamics and execution risks is essential.
Based on FMP financials and quantitative analysis
XERS Key Highlights
Market capitalization of $1.48B reflects strong investor interest and growth potential.
- Gross margin of 81.6% indicates high profitability relative to industry standards.
- P/E ratio of 1881.3 suggests high growth expectations from investors.
- Profit margin of 3.8% shows early-stage profitability as the company scales its operations.
- Beta of 0.99 indicates that the stock's volatility is in line with the broader market.
Who Are XERS's Competitors?
XERS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $433.73 | -1.95% | $234B | 86 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 90 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| INVA Innoviva, Inc. | $21.04 | -2.05% | $1.55B | 93 |
| MGTX MeiraGTx Holdings plc | $14.86 | -0.74% | $1.38B | 73 |
| LBRX LB Pharmaceuticals Inc | $47.23 | -3.49% | $1.35B | 73 |
| ETON Eton Pharmaceuticals, Inc. | $59.91 | -2.55% | $1.64B | 98 |
| CVAC CureVac N.V. | $4.66 | +0.00% | $1.05B | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are XERS's Key Strengths?
Strong gross margin of 81.6%, indicating effective cost management.
- Innovative product offerings addressing significant unmet medical needs.
- Proprietary formulation technologies that enhance drug delivery and patient compliance.
- Established presence in the biopharmaceutical market with a growing portfolio.
What Are XERS's Weaknesses?
Limited product portfolio compared to larger competitors.
- Dependence on a few key products for revenue generation.
- Potential challenges in scaling operations and production capacity.
- Relatively high P/E ratio may indicate overvaluation concerns.
What Could Drive XERS Stock Higher?
Potential new product launches utilizing XeriSol and XeriJect technologies.
- Continued market adoption of Gvoke in diabetes management.
- Development of new indications for Recorlev to expand its therapeutic use.
What Are the Key Risks for XERS?
Financial-distress signal — its Altman Z-Score of 0.87 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 1881.3 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Regulatory challenges that could delay product approvals.
- Competitive pressures from larger biopharmaceutical companies in the market.
- Dependence on key products for revenue generation may pose financial risks.
What Are the Growth Opportunities for XERS?
- Expansion of Gvoke market: The global glucagon market is projected to grow significantly, driven by increasing diabetes prevalence. Xeris's Gvoke, with its ready-to-use formulation, is well-positioned to capture market share, particularly as healthcare providers and patients seek more convenient treatment options. The anticipated growth in diabetes management could lead to increased sales, particularly over the next five years.
- New indications for Recorlev: Xeris is actively pursuing additional indications for Recorlev, which could significantly expand its market reach. The Cushing's syndrome market is estimated to grow, with increasing awareness and diagnosis rates. By leveraging its existing product and enhancing its therapeutic applications, Xeris could see substantial revenue growth from this segment over the next three to five years.
- Utilization of XeriSol and XeriJect technologies: The proprietary formulation platforms provide Xeris with a competitive advantage to develop new injectable therapies. The ability to create ready-to-use formulations could open up new therapeutic areas and patient populations, potentially leading to a robust pipeline of products in the coming years.
- Partnerships and collaborations: Xeris may explore strategic partnerships to enhance its product offerings and distribution capabilities. Collaborations with larger pharmaceutical companies could provide access to new markets and resources, facilitating faster product development and commercialization timelines.
- Market penetration in gastroenterology: With its existing product portfolio, Xeris can target the growing gastroenterology market. The increasing prevalence of gastrointestinal disorders presents an opportunity for the company to introduce innovative therapies and expand its customer base, particularly in the next five years.
What Threats Does XERS Face?
- Intense competition from established biopharmaceutical companies.
- Regulatory hurdles and challenges in obtaining product approvals.
- Market volatility affecting investor sentiment and stock performance.
- Potential for product recalls or safety concerns impacting reputation.
What Are XERS's Competitive Advantages?
- Proprietary formulation technologies (XeriSol and XeriJect) provide a competitive edge in drug delivery.
- Strong product portfolio addressing critical medical needs in endocrinology and neurology.
- Established market presence with innovative therapies that enhance patient care.
- Potential for expanding product indications and pipeline development creates barriers for competitors.
- Experienced leadership team with a track record in the biopharmaceutical industry.
What Does XERS Do?
Founded in 2005 and headquartered in Chicago, Illinois, Xeris Biopharma Holdings, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients in the fields of endocrinology, neurology, and gastroenterology. The company has made significant strides in addressing unmet medical needs through its proprietary formulation technologies, XeriSol and XeriJect, which allow for the creation of ready-to-use injectable medications. Xeris markets several key products, including Gvoke, a ready-to-use liquid glucagon designed for the treatment of severe hypoglycemia, which is particularly beneficial for patients with diabetes. Additionally, the company offers Keveyis, a therapy for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, and Recorlev, a cortisol synthesis inhibitor approved for treating endogenous hypercortisolemia in adults with Cushing's syndrome. Xeris is also focused on expanding its product pipeline, with ongoing development programs aimed at extending the indications of its existing products and introducing new therapies. With a workforce of 394 employees, Xeris is positioned to leverage its innovative technologies and product offerings to capture a significant share of the growing biopharmaceutical market.
What Products and Services Does XERS Offer?
- Develops and commercializes biopharmaceutical therapies for endocrinology, neurology, and gastroenterology.
- Markets Gvoke, a ready-to-use liquid glucagon for treating severe hypoglycemia.
- Offers Keveyis, a treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis.
- Provides Recorlev, a cortisol synthesis inhibitor for treating Cushing's syndrome.
- Utilizes proprietary formulation technologies, XeriSol and XeriJect, to enhance drug delivery and patient compliance.
- Has a pipeline of development programs aimed at expanding product indications and introducing new therapies.
How Does XERS Make Money?
- Generates revenue through the sale of marketed products, including Gvoke, Keveyis, and Recorlev.
- Utilizes proprietary technologies to develop innovative therapies that meet unmet medical needs.
- Focuses on expanding its product portfolio through research and development of new indications.
- May engage in partnerships or collaborations to enhance distribution and market access.
- Aims to capture market share in growing therapeutic areas such as endocrinology and gastroenterology.
What Industry Does XERS Operate In?
The biotechnology industry is experiencing robust growth, driven by advancements in drug development, increasing healthcare expenditures, and a rising prevalence of chronic diseases. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with significant contributions from innovative therapies targeting specific patient populations. Xeris Biopharma Holdings, Inc. operates in a competitive landscape characterized by established players and emerging companies, all vying for market share in endocrinology and neurology. The company's focus on proprietary formulation technologies gives it a competitive edge, enabling the development of unique products that cater to specific medical needs.
Who Are XERS's Key Customers?
- Patients with diabetes requiring glucagon for severe hypoglycemia management.
- Individuals suffering from periodic paralysis conditions needing effective treatment options.
- Patients diagnosed with Cushing's syndrome looking for cortisol synthesis inhibitors.
- Healthcare providers and institutions prescribing innovative therapies for chronic conditions.
- Pharmaceutical distributors and pharmacies stocking Xeris's products for patient access.
Forward Outlook
Wall Street analysts project Xeris Biopharma Holdings, Inc. revenue of about $387.5M for fiscal 2026, with EPS near $-0.01. The estimate reflects 5 contributing analysts.
Earnings Track Record
Xeris Biopharma Holdings, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 113.2% below estimates on average.
Financial Health
Xeris Biopharma Holdings, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.87 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -4.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.
Xeris Biopharma Holdings, Inc. (XERS) Valuation Context
Valued at $1.48B, XERS is classified as a small-cap stock. Relative to its peer group, XERS's quantitative score of 35/100 is below the peer average of 88/100.
XERS Revenue & Earnings Trend
In Q2 2026, XERS generated $92.1M in top-line revenue, marking a sequential increase of 10.8%. The company recorded a net loss of $31.1M, with diluted EPS of $-0.18. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, XERS averaged $-0.03 in diluted EPS.
Company Profile
Xeris Biopharma Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Chicago, US. The company is led by CEO John Shannon. XERS has traded publicly since 2018.
XERS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Xeris Biopharma's recent insider buying suggests those with the deepest knowledge of the company see potential upside, mirroring situations like when insiders loaded up on Amazon before its e-commerce dominance became clear.
- Community sentiment reflects optimism around Xeris's pipeline, with many believing their innovative drug delivery platforms could disrupt the market, similar to how CRISPR Therapeutics revolutionized gene editing.
- The overall market perception of Xeris is improving, with growing recognition of their potential in addressing unmet medical needs, akin to the initial excitement surrounding Moderna's mRNA technology.
- Bullish community members are actively highlighting positive clinical trial updates, fueling confidence in the company's ability to secure regulatory approvals, reminiscent of the anticipation surrounding Biogen's Alzheimer's drug.
Bear Case
- Recent insider activity, while showing some buying, is offset by previous selling, potentially signaling mixed feelings about the company's near-term prospects, similar to concerns surrounding Valeant Pharmaceuticals before its downfall.
- Community sentiment reveals skepticism about Xeris's ability to compete with established players in the diabetes and endocrinology space, echoing the challenges faced by smaller biotech firms against giants like Novo Nordisk.
- Market perception reflects concerns about Xeris's profitability and cash burn rate, raising questions about their long-term financial sustainability, much like the doubts that plagued many dot-com companies during the early 2000s.
- Bearish community members are pointing to potential regulatory hurdles and delays in drug approvals, casting doubt on the company's ability to meet its projected timelines, similar to the setbacks experienced by Omeros Corporation with its OMS721 drug.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $92M | -$31M | -$0.18 |
| Q1 2026 | $83M | $2M | $0.01 |
| Q4 2025 | $86M | $11M | $0.06 |
| Q3 2025 | $74M | $621,000 | $0.0030 |
Based on FMP financials and quantitative analysis
XERS Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
XERS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for XERS.
Price Targets
Wall Street price target analysis for XERS.
XERS MoonshotScore
What does this score mean?
The MoonshotScore rates XERS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: John Shannon
CEO
John Shannon has extensive experience in the biopharmaceutical industry, having held various leadership positions throughout his career. He has a strong background in operations, product development, and strategic planning. Prior to joining Xeris, he worked at several prominent pharmaceutical companies, where he was instrumental in driving growth and innovation.
Track Record: Under John Shannon's leadership, Xeris has successfully launched Gvoke and expanded its product portfolio. He has overseen the development of proprietary formulation technologies that enhance the company's competitive positioning in the market.
XERS Healthcare Stock FAQ
What does the AI Score mean for XERS?
XERS holds an AI Score of 35/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Xeris Biopharma Holdings, Inc. is a biopharmaceutical company specializing in therapies for endocrinology, neurology, and gastroenterology. The company is known for its innovative products …
What does Xeris Biopharma Holdings, Inc. do?
Xeris Biopharma Holdings, Inc. develops and commercializes innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company is known for its ready-to-use glucagon product, Gvoke, and other treatments like Keveyis and Recorlev, aimed at addressing specific medical needs.
What do analysts say about XERS stock?
Analysts generally view Xeris Biopharma Holdings, Inc. as a company with significant growth potential, particularly due to its innovative product offerings. The stock's valuation metrics, including a P/E ratio of 1881.3, suggest high expectations for future earnings growth, although this may also indicate some overvaluation concerns.
What are the main risks for XERS?
Xeris Biopharma Holdings, Inc. faces several risks, including potential regulatory hurdles that could delay product approvals and market entry. Additionally, the company operates in a competitive landscape with larger biopharmaceutical firms, which may impact its market share and pricing power. Dependence on key products for revenue generation further increases financial risk.
What are the key factors to evaluate for XERS?
Xeris Biopharma Holdings, Inc. (XERS) holds an AI score of 35/100 (low). P/E: 1881.3x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does XERS data refresh on this page?
XERS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven XERS's recent stock price performance?
Xeris Biopharma Holdings, Inc. (XERS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong gross margin of 81.6%, indicating effective cost management. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider XERS overvalued or undervalued right now?
Xeris Biopharma Holdings, Inc. (XERS) trades at 1881.3x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research XERS before investing?
Before investing in Xeris Biopharma Holdings, Inc. (XERS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data accuracy is based on the latest available information and may be subject to change.